PedAM
Pediatric Disease Annotations & Medicines
| oligodendroglioma | ||||
| Disease ID | 260 |
|---|---|
| Disease | oligodendroglioma |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:8) HP:0100843 | Glioblastoma | 14 HP:0002664 | Neoplasia | 9 HP:0009592 | Astrocytoma | 2 HP:0009733 | Glioma | 2 HP:0001876 | Low blood cell count | 1 HP:0030692 | Brain tumor | 1 HP:0000238 | Nonsyndromal hydrocephalus | 1 HP:0003003 | Colon cancer | 1 |
| Disease ID | 260 |
|---|---|
| Disease | oligodendroglioma |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:3) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:13) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1042522 | 18393224 | 7157 | TP53 | umls:C0028945 | BeFree | Aiming to study the role of TP53 Pro47Ser and Arg72Pro on glioma susceptibility and oncologic prognosis of patients, we investigated the genotype distribution of these SNPs in 94 gliomas (81 astrocytomas, 8 ependymomas and 5 oligodendrogliomas) and in 100 healthy subjects by the polymerase chain reaction-restriction fragment length polymorphism approach. | 0.020878618 | 2008 | TP53 | 17 | 7676154 | G | T,C |
| rs11133391 | 24135790 | 9575 | CLOCK | umls:C0028945 | BeFree | The variant allele for CLOCK rs11133391 under a recessive model increased risk of oligodendroglioma (OR 2.41; 95 % CI 1.31-4.42; p = 0.005), though not other glioma subtypes (p for heterogeneity = 0.0033). | 0.000271442 | 2013 | CLOCK | 4 | 55501788 | T | C |
| rs11540654 | 18393224 | 7157 | TP53 | umls:C0028945 | BeFree | Aiming to study the role of TP53 Pro47Ser and Arg72Pro on glioma susceptibility and oncologic prognosis of patients, we investigated the genotype distribution of these SNPs in 94 gliomas (81 astrocytomas, 8 ependymomas and 5 oligodendrogliomas) and in 100 healthy subjects by the polymerase chain reaction-restriction fragment length polymorphism approach. | 0.020878618 | 2008 | TP53 | 17 | 7676040 | C | T,G,A |
| rs118101777 | 25277207 | 3418 | IDH2 | umls:C0028945 | BeFree | The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K). | 0.245895776 | 2015 | IDH2 | 15 | 90087472 | C | T |
| rs118101777 | 25277207 | 3417 | IDH1 | umls:C0028945 | BeFree | The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K). | 0.138783028 | 2015 | IDH2 | 15 | 90087472 | C | T |
| rs121913500 | 23934175 | 3417 | IDH1 | umls:C0028945 | BeFree | We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111). | 0.138783028 | 2013 | IDH1 | 2 | 208248388 | C | T |
| rs121913500 | 25277207 | 3417 | IDH1 | umls:C0028945 | BeFree | The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K). | 0.138783028 | 2015 | IDH1 | 2 | 208248388 | C | T |
| rs121913500 | 25277207 | 3418 | IDH2 | umls:C0028945 | BeFree | The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K). | 0.245895776 | 2015 | IDH1 | 2 | 208248388 | C | T |
| rs121913500 | 22385787 | 3417 | IDH1 | umls:C0028945 | BeFree | The mutation analysis performed on the latter case with DNA separately sampled from the oligodendroglioma- like area and the astrocytoma-like area detected IDH1 G395A in both areas. | 0.138783028 | 2012 | IDH1 | 2 | 208248388 | C | T |
| rs121913500 | 23527265 | 3417 | IDH1 | umls:C0028945 | BeFree | This glioma xenograft is the first to display a pure oligodendroglioma histology and expression of R132H. | 0.138783028 | 2013 | IDH1 | 2 | 208248388 | C | T |
| rs121913503 | 25277207 | 3418 | IDH2 | umls:C0028945 | BeFree | The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K). | 0.245895776 | 2015 | IDH2 | 15 | 90088606 | C | T |
| rs121913503 | 25277207 | 3417 | IDH1 | umls:C0028945 | BeFree | The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K). | 0.138783028 | 2015 | IDH2 | 15 | 90088606 | C | T |
| rs1800371 | 18393224 | 7157 | TP53 | umls:C0028945 | BeFree | Aiming to study the role of TP53 Pro47Ser and Arg72Pro on glioma susceptibility and oncologic prognosis of patients, we investigated the genotype distribution of these SNPs in 94 gliomas (81 astrocytomas, 8 ependymomas and 5 oligodendrogliomas) and in 100 healthy subjects by the polymerase chain reaction-restriction fragment length polymorphism approach. | 0.020878618 | 2008 | TP53 | 17 | 7676230 | G | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:4) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0028945 | carmustine | D002330 | 154-93-8 | oligodendroglioma | MESH:D009837 | therapeutic | 15332326 | ||
| C0028945 | temozolomide | C047246 | 85622-93-1 | oligodendroglioma | MESH:D009837 | therapeutic | 20842591 | ||
| C0028945 | thiotepa | D013852 | 52-24-4 | oligodendroglioma | MESH:D009837 | therapeutic | 11303620 | ||
| C0028945 | vincristine | D014750 | - | oligodendroglioma | MESH:D009837 | therapeutic | 15015656 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D009837 | temodar | temozolomide | 5MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D009837 | temodar | temozolomide | 100MG/VIAL | POWDER;INTRAVENOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D009837 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |
| MESH:D009837 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |